Market Overview:
The global restless legs syndrome (RLS) market is expected to register a CAGR of 5.8% during the forecast period, 2018-2030. The market growth can be attributed to the increasing prevalence of RLS, rising awareness about RLS and its treatment options, and growing demand for pharmacological and non-pharmacological therapies for RLS. Based on type, the global restless legs syndrome (RLS) market is segmented into pharmacological therapy and non-pharmacological therapy. The pharmacological therapy segment is further sub-segmented into dopaminergic drugs, iron chelators, anticonvulsants/benzodiazepines/opioids combination therapies, and Others. The dopaminergic drugs sub-segment accounted for the largest share of the global pharmacological therapy segment in 2017 owing to their high efficacy in treating RLS symptoms. Based on application, the global restless legs syndrome (RLS) market is divided into below 35 years old, 35-50 years old,, above 50 years old segments. Among these age groups,, above 50 years old segment accounted for a larger share of the global restless legs syndrome (RLS) market in 2017 due to increasing geriatric population across globe.
Product Definition:
Restless legs syndrome (RLS) is a neurological disorder that affects the comfort of sitting or lying down. People with RLS have an irresistible urge to move their legs, often because they feel uncomfortable sensations like tingling, burning, itching, or cramping in their calves and thighs. The sensations usually occur when people are inactive and tend to disappear when they move around. Some people also have restless arms. Restless legs syndrome can significantly disrupt sleep and daily activities.
Pharmacological Therapy:
Pharmacological therapy is the use of drugs to restore normal neurological function. The most common symptom associated with RLS is uncomfortable or painful sensations that are experienced in the legs, often causing them to feel like they want to move but cannot. Other symptoms include restlessness, anxiety, and an urge or need to move the legs (the body part).
The exact cause of RLS remains unknown; however, research suggests that it may be due to a combination of genetic.
Non-Pharmacological Therapy:
Non-pharmacological therapy is a treatment approach that aims at the management of symptoms without using drugs to address the cause. It includes various techniques for managing chronic pain, such as acupuncture, trigger point massage, and shiatsu. Some of the other techniques are spinal manipulation, craniosacral therapy (head Massage), myofascial release (massage of connective tissues), and soft tissue massage.
Application Insights:
Below 35 years old application segment held the largest share of over 70.0% in 2017. This is due to a high prevalence of RLS among this age group which was observed in various studies conducted worldwide. Also, pharmacological treatment for RLS below 35 years is not very effective so non-pharmacological therapy is preferred for this age group instead of pharmacological therapy as there are no proven benefits with the use of these therapies yet.
35-50 years old application segment held a significant share in 2017 and it will grow at a steady growth rate during the forecast period owing to increasing awareness about Restless Legs Syndrome (RLS) and growing acceptance for treatment options other than medication for this condition, especially among women population who prefer natural treatments over medication when it comes to their health concerns.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period. This can be attributed to increasing awareness about RLS, rising prevalence of restless legs syndrome among geriatric population and growing demand for non-benzodiazepine drugs due to their safer side effect profile compared with benzodiazepines.
Asia Pacific is estimated to witness lucrative growth over the coming years owing to a rise in disposable income, improving healthcare facilities and an increase in patient awareness about Restless Legs Syndrome (RLS) treatment options available in emerging economies such as China & India & Australia.
Moreover, countries such as Japan are amongst those that have adopted western culture.
Growth Factors:
- Increasing awareness about restless legs syndrome (RLS) and its symptoms will drive the growth of the RLS market.
- The increasing prevalence of RLS will also fuel the growth of the market.
- Rising demand for effective treatment options for RLS will propel the growth of this market.
- The increasing number of research studies on restless legs syndrome is expected to create new opportunities in this market during the forecast period.
- Growing demand from emerging markets is likely to provide significant impetus to the growth of this market in future
Scope Of The Report
Report Attributes
Report Details
Report Title
Restless Legs Syndrome Market Research Report
By Type
Pharmacological Therapy, Non-Pharmacological Therapy
By Application
Below 35 YearsOld, 35-50 Years Old, Above50 YearsOld
By Companies
GlaxoSmithKline plc., Ligand Pharmaceuticals Incorporated, axxonis Pharma AG, Kyowa Hakko Kirin, Jazz Pharmaceuticals, Omeros Corporation, Manhattan Pharmaceuticals, Boehringer Ingelheim GmbH, UCB SA
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
214
Number of Tables & Figures
150
Customization Available
Yes, the report can be customized as per your need.
Global Restless Legs Syndrome Market Report Segments:
The global Restless Legs Syndrome market is segmented on the basis of:
Types
Pharmacological Therapy, Non-Pharmacological Therapy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Below 35 YearsOld, 35-50 Years Old, Above50 YearsOld
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GlaxoSmithKline plc.
- Ligand Pharmaceuticals Incorporated
- axxonis Pharma AG
- Kyowa Hakko Kirin
- Jazz Pharmaceuticals
- Omeros Corporation
- Manhattan Pharmaceuticals
- Boehringer Ingelheim GmbH
- UCB SA
Highlights of The Restless Legs Syndrome Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Pharmacological Therapy
- Non-Pharmacological Therapy
- By Application:
- Below 35 YearsOld
- 35-50 Years Old
- Above50 YearsOld
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Restless Legs Syndrome Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Restless legs syndrome (RLS) is a neurological disorder characterized by an overwhelming urge to move the legs, often accompanied by an intense feeling of restlessness. The cause is unknown, but it may be related to abnormalities in the nervous system.
Some of the key players operating in the restless legs syndrome market are GlaxoSmithKline plc., Ligand Pharmaceuticals Incorporated, axxonis Pharma AG, Kyowa Hakko Kirin, Jazz Pharmaceuticals, Omeros Corporation, Manhattan Pharmaceuticals, Boehringer Ingelheim GmbH, UCB SA.
The restless legs syndrome market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Restless Legs Syndrome Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Restless Legs Syndrome Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Restless Legs Syndrome Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Restless Legs Syndrome Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Restless Legs Syndrome Market Size & Forecast, 2020-2028
4.5.1 Restless Legs Syndrome Market Size and Y-o-Y Growth
4.5.2 Restless Legs Syndrome Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Pharmacological Therapy
5.2.2 Non-Pharmacological Therapy
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Below 35 YearsOld
6.2.2 35-50 Years Old
6.2.3 Above50 YearsOld
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Restless Legs Syndrome Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Restless Legs Syndrome Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Pharmacological Therapy
9.6.2 Non-Pharmacological Therapy
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Below 35 YearsOld
9.10.2 35-50 Years Old
9.10.3 Above50 YearsOld
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Pharmacological Therapy
10.6.2 Non-Pharmacological Therapy
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Below 35 YearsOld
10.10.2 35-50 Years Old
10.10.3 Above50 YearsOld
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Pharmacological Therapy
11.6.2 Non-Pharmacological Therapy
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Below 35 YearsOld
11.10.2 35-50 Years Old
11.10.3 Above50 YearsOld
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Pharmacological Therapy
12.6.2 Non-Pharmacological Therapy
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Below 35 YearsOld
12.10.2 35-50 Years Old
12.10.3 Above50 YearsOld
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Pharmacological Therapy
13.6.2 Non-Pharmacological Therapy
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Below 35 YearsOld
13.10.2 35-50 Years Old
13.10.3 Above50 YearsOld
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Restless Legs Syndrome Market: Competitive Dashboard
14.2 Global Restless Legs Syndrome Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 GlaxoSmithKline plc.
14.3.2 Ligand Pharmaceuticals Incorporated
14.3.3 axxonis Pharma AG
14.3.4 Kyowa Hakko Kirin
14.3.5 Jazz Pharmaceuticals
14.3.6 Omeros Corporation
14.3.7 Manhattan Pharmaceuticals
14.3.8 Boehringer Ingelheim GmbH
14.3.9 UCB SA
